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The transport through the nuclear pore complex is used by cancer cells to evade tumor-
suppressive mechanisms. Several tumor-suppressors have been shown to be excluded
from the cell nucleus in cancer cells by the nuclear export receptor CRM1 and abnormal
expression of CRM1 is oncogenic. Inhibition of CRM1 has long been postulated as
potential approach for the treatment of cancer and to overcome therapy resistance.
Furthermore, the nuclear export of viral components mediated by the CRM1 is crucial in
various stages of the viral lifecycle and assembly of many viruses from diverse families,
including coronavirus. However, the first nuclear export inhibitors failed or never entered
into clinical trials. More recently CRM1 reemerged as a cancer target and a successful
proof of concept was achieved with the clinical approval of Selinexor. The chemical
complexity of natural products is a promising perspective for the discovery of new nuclear
export inhibitors with a favorable toxicity profile. Several screening campaigns have been
performed and several natural product-based nuclear export inhibitors have been
identified. With this review we give an overview over the role of CRM1-mediated
nuclear export in cancer and the effort made to identify and develop nuclear export
inhibitors in particular from natural sources.
Keywords: CRM1, nuclear export, natural products (NP), leptomycin B, Selinexor, high content screening (HCS)INTRODUCTION
Human diseases often involve alterations in the structure, localization, interactions, and as a
consequence, the function of cellular proteins (Hung and Link, 2011). Normal cell physiology
requires a tightly regulated, coordinated activity of thousands of proteins, that must be in the right
place at the right time. Protein function depends on the subcellular localization as it determines
access of the protein to binding partners and enzymes that catalyze post-translational modification
and facilitates its contribution to functional networks. For example, transcription factors have to be
in the cell nucleus in order to have access to the target gene promoters and to exert their
transcriptional activity. With the exception of red blood cells, all eukaryotic cells contain a nucleus
which is surrounded by a nuclear envelope made up of two lipid bilayer membranes. The nuclear
envelope represents a greater physical barrier than the single lipid bilayer of the plasma membrane.
The movement of molecules between the nucleoplasm and the cytoplasm is controlled by nuclear
pore complexes (NPCs). The NPC is one of the largest cellular protein complexes and is responsible
for the controlled passage of macromolecules into and out of the nucleus. The NPCs are permeable
only to small molecules such as salts, nucleotides, small proteins. Proteins over 40 kDa are requiredin.org May 2020 | Volume 11 | Article 6251
Ferreira et al. CRM1 Inhibitorsto be moved through the nuclear pore complex (NPCs) by
soluble nuclear transport receptors (Cautain et al., 2015b).
Proteins that enter and exit through the NPC usually contain
specific transport signals namely a nuclear localization signal
(NLS) or a nuclear export signal (NES). These sequences are
recognized by soluble transport receptors of the karyopherin family.THE CRM1 EXPORT RECEPTOR
The best studied export protein is chromosome region maintenance
1 (CRM1 also known as XPO1 or exportin 1) (Fornerod et al., 1997;
Fukuda et al., 1997; Ossareh-Nazari et al., 1997; Kudo et al., 1998).
CRM1 is expressed in all eukaryotic cells. CRM1 belongs to the
karyopherin-b family of transport receptors and mediates the
nuclear exports of proteins that contain leucine-rich NESs
(Fukuda et al., 1997). Over 200 proteins have been verified as
cargoes of CRM1. Ran-GTP binds to CRM1 in the nucleus causing
an increased affinity to the NES containing cargo protein and a
complex between Ran, CRM1 and the cargo forms. This complex is
exported through the NPC into the cytoplasm where Ran-GTP is
converted into Ran-GDP and the complex dissociates. Human
CRM1 consists of 1071 amino-acid residues and contains several
functional regions (Figure 1). CRM1 is made up of 21 tandemly
repeated, 37–47 amino acid long modules called HEAT protein
domains (Dong et al., 2009a; Dong et al., 2009b; Monecke et al.,
2009). Each repeat forms a hairpin of two helices called A and B
helices building a ring-shaped structure. While the outer surface of
the ring comprise the A helices, the B helices form the inner surface
(Güttler et al., 2010; Koyama and Matsuura, 2010; Dian et al., 2013;
Monecke et al., 2013; Saito and Matsuura, 2013). The NES binding
cleft is formed by HEAT repeats 11 and 12 at the outer surface of
CRM1. The N-terminal CRIME domain shares sequence homology
with importin-b and is involved in binding to RanGTP. The acidic
loop within HEAT-repeat 9 also contributes to RanGTP binding
and is thought to inhibit the interaction with NES in the absence of
RanGTP.While the central part of CRM1 is involved the interaction
with NES, the C-terminal end of CRM1 is thought to modulate its
affinity to NES (Dong et al., 2009a; Dian et al., 2013).Frontiers in Pharmacology | www.frontiersin.org 2The Role of CRM1 in Cancer
CRM1 is responsible for the nuclear export of a large number of
tumor suppressor and oncogenic proteins including
retinoblastoma, APC, FOXO proteins, INI1/hSNF5, galectin-3,
Bok, NPM1, RASSF2, Merlin, p53, p21CIP, p27KIP1, N-WASP/
FAK, estradiol receptor, Tob, BRAC1, BCR–ABL and eIF4E.
Importantly, many of these proteins were found to be
mislocalized in cancer cells (Hill et al., 2014). RNAi-mediated
silencing of the CRM1 induced nuclear retention of p53 and cell
death in cervical cancer cell lines (Santiago et al., 2013). Somatic
mutations in CRM1 have been identified in chronic lymphocytic
leukemia (Puente et al., 2011) and in other hematological
malignancies (Sendino et al., 2018). The great majority of these
mutations affect a single amino acid at position 571. The E571K
mutation localizes near the NES-binding site and substitutes a
glutamic acid with a lysine. This variation replaces a negatively
charged residue with a positively charged amino acid and might
lead to an increased affinity for NES (Garcı ́a-Santisteban
et al., 2016).
The expression of CRM1 is increased in a broad variety of
cancer types including cervical (van der Watt et al., 2009),
ovarian (Noske et al., 2008), kidney (Inoue et al., 2013), lung
(Gao et al., 2015) and gastric cancers (Zhou et al., 2013), as well
as in glioma (Shen et al., 2009), osteosarcoma (Yao et al., 2009),
esophageal carcinoma (Van DerWatt et al., 2014), hepatocellular
carcinoma (Zheng et al., 2014), multiple myeloma (Schmidt
et al., 2013), acute myeloid leukemia (Kojima et al., 2013),
chronic myeloid/lymphoid leukemia (Lapalombella et al.,
2012), mantle cell lymphoma (Yoshimura et al., 2014) and
plasma cell leukemia (Tai et al., 2014). In line with these
observations, high level of CRM1 expression is correlated with
tumor size, the presence of distant metastasis and poor prognosis
in many cancer types. Therefore, CRM1 expression might have
the potential to predict clinical outcome for several human
tumor types. Importantly, CRM1 also plays an important role
in drug resistance (Turner and Sullivan, 2008; Turner et al.,
2012). Several different nuclear export inhibitors (NEIs) have
been shown to sensitize drug-resistant cancer cells to anti-cancer
drugs. These data suggest that interfering with the nuclear exportFIGURE 1 | Architecture of CRM1. CRM1 consists of 21 HEAT repeats each composed of two anti-parallel helices (A, B) connected by a linker loop. The N-
terminal CRIME domain and the acidic loop contribute to RanGTP binding. The A helices of HEAT tandem 11 and 12 form the NES cleft. HEAT repeats 11–16 are
involved in cargo e.g. Snurportin1 (Spn1) binding.May 2020 | Volume 11 | Article 625
Ferreira et al. CRM1 Inhibitorsof tumor suppressor proteins or cell cycle inhibitors might
contribute to overcome therapy resistance.
Binding of CRM1 to Leptomycin B
The progress made in understanding CRM1-mediated nuclear
export is greatly based on the identification of Leptomycin B
(LMB) as a CRM1 inhibitor (Kudo et al., 1998). LMB is natural
product polyketide isolated from Streptomyces and has been
originally discovered as a potent antifungal compound
(Hamamoto et al., 1983). LMB contains two conjugated dienes,
an a,b-unsaturated d-lactone, a b-hydroxy-ketone moiety, and a
terminal carboxylate (Figure 2A). Its molecular weight is 540-
Da. LMB binds covalently to a cysteine residue in CRM1 in
HEAT repeat 11 of CRM1 (Cys-528 in the human CRM1) whichFrontiers in Pharmacology | www.frontiersin.org 3is located in the NES-binding groove by a Michael-type addition
reaction via its a,b-unsaturated d-lactone moiety (Kudo et al.,
1999a). As LMB modifies a cysteine residue in CRM1 critical for
NES-cargo binding, it inhibits the formation of the NES–CRM1–
RanGTP complex and thereby the export of the cargo protein to
the cytoplasm. Surprisingly, CRM1 acts as an enzyme
hydrolyzing the lactone of LMB and thereby optimizing the
LMB–CRM1 interaction. CRM1-induced modification of LMB
leads to the irreversibility of the conjugation (Sun et al., 2013).
LMB showed promising anti-cancer activity in preclinical
experiments, but failed in clinical trial due to its systemic
toxicity (Newlands et al., 1996). The dose limiting toxicity
associated with LMB is thought to be due to a permanent
block of nuclear export of essential macromolecules.A
FIGURE 2 | ContinuedMay 2020 | Volume 11 | Article 625
B
FIGURE 2 | Structures of CRM1 inhibitors. (A) Natural compounds: (1) Leptomycin B, (2) Acetoxychavicol acetate (3) Ratjadone, (4) Valtrate, (5) Anguinomycin C, (6)
15d-PGJ2, (7) Plumbagin, (8) Curcumin (9) Piperlongumine (B) Synthetic compounds: (10) CBS9106, (11) KPT-330 (Selinexor).
Ferreira et al. CRM1 InhibitorsTARGETING THE CRM1-DRIVEN
NUCLEAR EXPORT
Due to the crucial regulatory role and the alteration in human
cancer, CRM1 has emerged as a therapeutic target for anticancer
therapy. Although, altered CRM1 expression or activity is not
always the driving force behind protein mislocalization, the
inhibition of the nuclear export can prevent or correct aberrant
subcellular protein localization (Hung and Link, 2011). For
example, FOXO proteins are shuttled from the cell nucleus
where they can act as tumor suppressors to the cytoplasm via
CRM1-mediated nuclear export when they are phosphorylatedFrontiers in Pharmacology | www.frontiersin.org 4by the AKT. AKT is a serine/threonine protein kinase and a key
component of the PI3K/AKT signaling pathway, which is
thought to be the most frequently activated signaling pathway
in human cancer. While NEIs do not interfere with the signaling
event that led to cytoplasmic mislocalization of FOXOs, they can
trap FOXO factors in the cell nucleus and thereby promote their
tumor suppressive function. Indeed, the clinically approved NEI
Selinexor partially acts through trapping FOXO into the nucleus
(Corno et al., 2018). Therefore, NEIs might not only be useful to
treat tumors with altered CMR1 expression or function, but
relocalize many tumor suppressor proteins or even mislocalize
and thereby inactivate oncogenic proteins (Hung and Link,May 2020 | Volume 11 | Article 625
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nuclear export has been developed over the last decades and the
first generation of NEIs including LMB turned out to be to toxic
to be used in the clinic, only more recently a significant
therapeutic window for these inhibitors has been reported
(Mutka et al., 2009). The therapeutic indications of these
inhibitors are not limited to cancer but have also the potential
to be used as antiviral agents.
Natural Product and Synthetic NEIs
The known NEIs can be classified into natural products and
synthetic NEIs (Figures 2A, B). Natural product NEIs are
derived from bacterial, plant, fungal or animal sources (Table 1)
(Sun et al., 2016). The bacterial NEIs contain a polyketide chain
with a lactone ring and include LMB, anguinomycin A/B/C/D and
ratjadone A/C (Hamamoto et al., 1983; Köster et al., 2003; Bonazzi
et al., 2010). Anguinomycins are analogs of LMB isolated from
Streptomyces sp. Ratjadone is a cytotoxin isolated from
myxobacteria from soil at Cala Ratjada on Mallorca island.
These polyketide natural products covalently bind to Cys-528 in
the human CRM1 and have IC50 values in the low nanomolar
range (Sun et al., 2013). However, these NEIs are associated with
severe dose limiting toxicities. While they are very powerful tools
to study CRM1 function, they are not useful as therapeutic agents.
NEIs derived from plants include acetoxychavicol acetate,
valtrate, piperlongumine, curcumin, dibenzylideneacetone,
gonionthalamin, and plumbagin. They are thought to bind to
Cys528 of CRM1 with low affinity and inhibit CRM1 in the
micromolar range. Acetoxychavicol acetate (ACA) is found in
Alpinia galangal and was identified as an inhibitor of CRM1-
dependent nuclear export by screening extracts from more than
600 medical plants (Ye and Li, 2006). Pharmacophore features of
ACA have been defined. Similar to ACA, the chemically
unrelated valtrate was found through screening 200 plant
extracts. Valtrate is an iridoid ester with moderate lipophilicity
extracted from Valerianae radix (Murakami et al., 2002). Both,
ACA and valtrate have been shown to inhibit virus production
(Watanabe et al., 2011). Furthermore, two food additives, namely
piperlongumine and curcumin were found to inhibit CRM1-
mediated nuclear export. The alkaloid piperlongumine is
extracted from Piper longum Linn and exhibits multiple
beneficial effects including selective cytotoxicity against severalFrontiers in Pharmacology | www.frontiersin.org 5cancer cell lines. Accordingly, piperlongumine was shown to
inhibit the CRM1 dependent transport of tumor suppressor
proteins including FOXO1 and p21 (Niu et al., 2015b).
Curcumin is a polyphenol compound present in Curcuma
longa plant and is the main component of the Indian spice
turmeric. It is known for its antioxidant, anti‐cancer and anti‐
inflammatory effects. Curcumin and its structural analogue
dibenzylideneacetone were shown to prevent the cytoplasmic
accumulation of a reporter protein fused with NES in a CRM1-
dependent manner (Niu et al., 2013). Similarly, a nuclear export
assay and molecular modeling were used to characterize the
styryl- lactone compound goniothalamin present in
Gon i o tha l amus mac rophy l l u s a s an inh ib i t o r o f
nucleocytoplasmic transport via CRM1 (Wach et al., 2010).
The natural bicyclic naphthoquinone plumbagin found in
roots of plumbaginaceae which have been used in Indian
traditional medicine was also identified as a CRM1 inhibitor
and capable of blocking the nuclear export of RanBP1 and
FOXO1 (Liu et al., 2014). Interestingly, the endogenous, anti-
inflammatory prostaglandin 15d-PGJ2 has been shown to inhibit
CRM1 by a LMB-like mechanism but with much less potency
(Hilliard et al., 2010). Conversely, the mechanism of action for
the diterpenoid oridonin present in Rabdosia rubescens remains
to be determined. Oridonin inhibits inflammation and
carcinogenesis and has been used in Chinese traditional
medicine. It was shown to induce nuclear translocation of
Crm1 and to increase the expression and nuclear accumulation
of nucleoporin98, involved in Crm1-mediated nuclear export (Li
et al., 2014).
The failure of the first generation of NEIs in clinical trials
raised skepticism about the therapeutic potential of inhibiting
nuclear export. Furthermore, preclinical evaluation of the semi-
synthetic LMB derivative KOS-2462 (Mutka et al., 2009) and the
synthetic small molecule CRM1 inhibitor CBS9106 (Sakakibara
et al., 2011) did not lead to their clinical development (Parikh
et al., 2014). The realization that there is the possibility of
targeting nuclear export with an acceptable level of toxicity
have spurred the development of second generation, synthetic
CRM1 inhibitors, including CBS9106 (Sakakibara et al., 2011),
PKF050-638 (Daelemans et al., 2002), 5219668 (Kau et al., 2003),
compound3/4 (Monovich et al., 2009) and S109 (Niu et al.,
2015a) and Selective Inhibitors of Nuclear Export (SINEs) (KalidTABLE 1 | Natural product nuclear export inhibitors.
Natural Product Source Mode of Action Effect
Leptomycin B Streptomyces CRM1-Cys528 Potent nuclear export inhibition
Anguinomycin Streptomyces CRM1-Cys528 Potent nuclear export inhibition
Ratjadone Myxobacteria CRM1-Cys528 Potent nuclear export inhibition
Acetoxychavicol acetate Alpinia galangal CRM1-Cys528 Inhibit viral production
Valtrate Valerianae Radix CRM1-Cys528 Inhibit viral production
Piperlongumine Piper longum CRM1-Cys528 Nuclear tumor suppressor proteins
Curcumin Curcuma longa CRM1-Cys528 Nuclear reporter protein
Gonionthalamin Goniothalamus macrophyllus CRM1-Cys528 Nuclear reporter protein
Plumbagin Plumbaginaceae CRM1-Cys528 Nuclear RanBP1 and FOXO1
15d-PGJ2 Human prostaglandine CRM1-Cys528 Nuclear TFIIAa
Oridonin Rabdosia rubescens n/d Increased and nuclear Nup98
MDN-0105 Fungal metabolite CRM1 n/d Nuclear FOXO3, Rev, NF-kBMay 2020 | Volume 11 | Article 625
BOX 1 | Approaches for identifying CRM1 Inhibitors.
Approaches for identifying CRM1 Inhibitors
Several methods are useful in identifying CRM1 inhibitors including gene
reporter assays and image-based high content screening.
Gene reporter assay
Daelemans et al. reported a screening campaign to identify inhibitors of the
CRM1-mediated nuclear export of HIV-1 Rev protein using Rev-dependent
luciferase reporter gene assay in Jurkat T cells (Daelemans et al., 2002). The
reporter gene is flanked by splice sites under the control of the HIV-1 Rev
response element (RRE). The cells are co-transfected firefly luciferase reporter
gene fused to the p17 gag sequences and the RRE, flanked by the HIV-1 major
splice sites, and driven by the CMV promoter and a vector that expresses HIV-1
Rev protein. Inhibitors of the Rev function cause a dose-dependent inhibition of
Rev-dependent luciferase expression. The specificity of the compounds on Rev
function can be tested on a Rev independent luciferase gene.
High Content Screening (HCS)
Image-based HCS (Zanella et al., 2010) has been widely used to screen for
CRM1 inhibitors. The U2nesRELOC system uses human U2OS osteosarcoma
cells that stably express a green fluorescent protein (GFP)-labeled Rev reporter
protein that contains a heterologous nuclear export signal (NES). The
fluorescent signal of U2nesRELOC cells is exclusively expressed in the
cytoplasm. Treatment with NEIs such as LMB the fluorescent reporter rapidly
accumulates in the nucleus (Cautain et al., 2015a). Acquisition and analysis of
images is based on high content screening technology (Zanella et al., 2010).
LMB is used as a positive control. As the cell nucleus is stained with 4,6-
Ferreira et al. CRM1 Inhibitorset al., 2012; Lapalombella et al., 2012; Ranganathan et al., 2012).
The first molecule of this family of small molecule compounds
was found by a screening effort aimed to identify new anti-HIV
Rev inhibitors (Daelemans et al., 2002). The authors analyzed a
collection of small molecules using a Rev-dependent luciferase
reporter assay and identified PKF050-638 as an anti-viral agent.
The SINE compounds include selinexor (KPT-330), verdinexor
(KPT-335), KPT-185, KPT-276, and KPT-251. SINEs covalently
bind to Cysteine 528 residue in a slowly reversible fashion. While
a homozygous or heterozygous mutation of Cys528 conferred
resistance to SINE treatment, the E571K mutation did not affect
their inhibitory efficacy on the CRM1-mediated nuclear export
(Garcıá-Santisteban et al., 2016; Jardin et al., 2016). Although,
LMB and SINE share the same target amino acid residue of
CRM1, SINEs are smaller and occupy less space of theNES groove
(Lapalombella et al., 2012; Etchin et al., 2013; Haines et al., 2015;
Hing et al., 2016). In addition, SINEs don´t undergo hydrolysis
upon binding to CRM1 and don´t form a salt bridge with CRM1
(Etchin et al., 2013; Sun et al., 2013;Haines et al., 2015). Therefore,
the binding of SINEs to CRM1 is slowly reversible (Sun et al.,
2013). As a consequence inhibition of CRM1 mediated nuclear
export is transient which might explain the reduced toxicity of
SINEs compared to the one associated with LMB. SINE
compounds have been analyzed in preclinical and clinical
studies for numerous solid and hematologic cancers. These
clinical trials include the treatment of lymphomas (non-
Hodgkin’s and diffuse large B-cell lymphoma), gliomas,
sarcomas, breast cancer, lung cancer, pancreatic cancer,
Myelodysplastic Syndromes (MDS), acute myeloid leukemia
(AML), Acute lymphocytic leukemia (ALL) multiple myeloma,
gastric cancer, esophageal cancer, colorectal cancer, prostate
cancer, melanoma, thymic cancer, and gynecologic cancers
(Wang and Liu, 2019). The spectrum of malignancies evaluated
in these clinical trials underlines the broad applicability of CRM1
inhibitors (Wang and Liu, 2019). The recent clinical approval of
Selinexor (Xpovio) also known as KPT-330 is the proof of concept
for the therapeutic utility of manipulating the nuclear export.
Selinexor has been approved for the treatment of patients with
relapsed refractory multiple myeloma (Chari et al., 2019). Side
effects associated with SINE treatment are less severe as expected
from agents capable of inhibiting a core physiological process as
the nuclear export of macromolecule.diamidino-2-phenylindole (DAPI), the cell nucleus can be visualized and the
definition of its boundaries can support automated image analysis (Machado
et al., 2019). In order to identify small molecule agents that inhibit the nuclear
export of tumor suppressors from the nucleus via CRM1, we used the
U2nesRELOC system to screen a library of natural product extracts from
microbial origin. The collection of products was enriched in secondary
metabolites (Cautain et al., 2014). 14,000 different extracts were evaluated for
the capacity to accumulate the fluorescent signal in the nucleus of the reporter
cells. From the 14,000 extracts, 6000 were obtained from fungi, another 6000
were derived from actinomycetes, and the remaining 2000 extracts were of
marine actinomycete origin. 12 extracts with nuclear export inhibitory activities
that were not associated with previously known active metabolites were
identified. After purification of active compounds, several chemical structures
of novel nuclear export inhibitors were identified including the fungal metabolite
MDN-0105.NATURAL PRODUCTS AS A SOURCE OF
NOVEL CRM1 INHIBITORS
Natural products are considered as an extremely valuable source
for the discovery of new drugs against diverse pathologies. As yet
only a fraction of the diversity of bioactive compounds has been
explored and opportunities for discovering new natural products
leading to new drugs are huge. Several approaches for identifying
CRM1 Inhibitors have been reported (Box 1). Bacterial CRM1
inhibitors like LMB might provide Streptomyces with theFrontiers in Pharmacology | www.frontiersin.org 6capacity to kill fungi which restrict their growth. CRM1 is
essential for the fungus. A change from Cys529 to Ser in a
CRM1 mutant of Saccharomyces pombe render the fungus
resistant to LMB, whereas Saccharomyces cerevisiae which
does not carry a cysteine at that position is LMB insensitive
(Kudo et al., 1999b; Yashiroda and Yoshida, 2003). Many
organisms might have developed similar or slightly different
capacities to fight and resist competitors. Therefore, is not fare-
fetched to expect metabolites from natural origin to represent a
rich source of potential nuclear export inhibitors with novel
modes of action. Mutating Cys528 is an obvious yet not
evaluated possibility of cancer cells to escape the selective
pressure imposed by the treatment with covalent CRM1
inhibitors. It is also possible, that the therapeutic efficacy of
CRM1 inhibition might also be limited in cancer cells that
strongly overexpress CRM1, but increasing the dosing of
covalent CRM1 inhibitors is impossible due to on-target and
off-target toxicity. For the time being, all known CRM1May 2020 | Volume 11 | Article 625
Ferreira et al. CRM1 Inhibitorsinhibitors act through covalent binding to Cys528 of CRM1. In
addition, they all contain a Michael acceptor which makes them
prone to target off effects by non-specific interaction with other
targets. The perspective to identify and develop non-covalent
inhibitors of CRM1 holds promise to increase efficacy by
reducing drug resistance and on-target and off-target toxicity.
Natural product drug discovery is associated with specific
limitations including the complexity of natural product
chemistry, intellectual property landscape and sustainable
supply. Bioavailability challenges associated with natural
products could potentially be addressed by designing suitable
drug delivery strategies.
CONCLUDING REMARKS
Interrupting the nuclear export of viral and cellular proteins
mediated by CRM1 has emerged as an extremely promising
therapeutic strategy to treat patients with viral infections and
cancer. The clinical approval of the first-in-class CRM1 inhibitor
Selinexor has proven the therapeutic potential of CRM1
inhibition for the treatment of cancer. Compounds derived
from natural sources hold promise to support the discovery of
new NEIs with a novel mode of action. Image-based high content
screening of extract and compound collections is a very efficient
way to identify natural products with inhibitory effect on the
nuclear export.Frontiers in Pharmacology | www.frontiersin.org 7AUTHOR CONTRIBUTIONS
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target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic
approach in cancer. Cancer Drug Resist 1, 139–163. doi: 10.20517/cdr.2018.09
Shen, A., Wang, Y., Zhao, Y., Zou, L., Sun, L., and Cheng, C. (2009).
Expression of crm1 in human gliomas and its significance in p27
express ion and cl inical prognosis . Neurosurgery 65, 153–160.
doi: 10.1227/01.NEU.0000348550.47441.4B
Sun, Q., Carrasco, Y. P., Hu, Y., Guo, X., Mirzaei, H., MacMillan, J., et al. (2013).
Nuclear export inhibition through covalent conjugation and hydrolysis ofMay 2020 | Volume 11 | Article 625
Ferreira et al. CRM1 InhibitorsLeptomycin B by CRM1. Proc. Natl. Acad. Sci. U. S. A. 110, 1303–1308.
doi: 10.1073/pnas.1217203110
Sun, Q., Chen, X., Zhou, Q., Burstein, E., Yang, S., and Jia, D. (2016). Inhibiting
cancer cell hallmark features through nuclear export inhibition. Signal
Transduction Targeting Ther. 1, 16010. doi: 10.1038/sigtrans.2016.10
Tai, Y. T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M. Y., Cea, M., et al.
(2014). CRM1 inhibition induces tumor cell cytotoxicity and impairs
osteoclastogenesis in multiple myeloma: Molecular mechanisms and
therapeutic implications. Leukemia 28, 155–165. doi : 10.1038/
leu.2013.115
Turner, J., and Sullivan, D. (2008). CRM1-Mediated Nuclear Export of Proteins
and Drug Resistance in Cancer. Curr. Med. Chem. 15, 2648–2655. doi: 10.2174/
092986708786242859
Turner, J. G., Dawson, J., and Sullivan, D. M. (2012). Nuclear export of proteins
and drug resistance in cancer. Biochem. Pharmacol. 83, 1021–1032.
doi: 10.1016/j.bcp.2011.12.016
van der Watt, P. J., Maske, C. P., Hendricks, D. T., Parker, M. I., Denny, L.,
Govender, D., et al. (2009). The Karyopherin proteins, Crm1 and Karyopherin
b1, are overexpressed in cervical cancer and are critical for cancer cell survival
and proliferation. Int. J. Cancer 124, 1829–1840. doi: 10.1002/ijc.24146
Van Der Watt, P. J., Zemanay, W., Govender, D., Hendricks, D. T., Parker, M. I.,
and Leaner, V. D. (2014). Elevated expression of the nuclear export protein,
Crm1 (exportin 1), associates with human oesophageal squamous cell
carcinoma. Oncol. Rep. 32, 730–738. doi: 10.3892/or.2014.3231
Wach, J. Y., Güttinger, S., Kutay, U., and Gademann, K. (2010). The cytotoxic
styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport.
Bioorg. Med. Chem. Lett. 20, 2843–2846. doi: 10.1016/j.bmcl.2010.03.049
Wang, A. Y., and Liu, H. (2019). The past, present, and future of CRM1/XPO1
inhibitors. Stem Cell Investig. 6, 6. doi: 10.21037/sci.2019.02.03
Watanabe, K., Takatsuki, H., Sonoda, M., Tamura, S., Murakami, N., and
Kobayashi, N. (2011). Anti-influenza viral effects of novel nuclear export
inhibitors from Valerianae Radix and Alpinia galanga. Drug Discovery Ther.
5, 26–31. doi: 10.5582/ddt.v5.1.26Frontiers in Pharmacology | www.frontiersin.org 9Yao, Y., Dong, Y., Lin, F., Zhao, H., Shen, Z., Chen, P., et al. (2009). The expression
of CRM1 is associated with prognosis in human osteosarcoma. Oncol. Rep. 21,
229–235. doi: 10.3892/or_00000213
Yashiroda, Y., and Yoshida, M. (2003). Nucleo-Cytoplasmic Transport of Proteins
as a Target for Therapeutic Drugs. Curr. Med. Chem. 10, 741–748.
doi: 10.2174/0929867033457791
Ye, Y., and Li, B. (2006). 1′S-1′-acetoxychavicol acetate isolated from Alpinia
galanga inhibits human immunodeficiency virus type 1 replication by blocking
Rev transport. J. Gen. Virol. 87, 2047–2053. doi: 10.1099/vir.0.81685-0
Yoshimura, M., Ishizawa, J., Ruvolo, V., Dilip, A., Quintás-Cardama, A.,
McDonnell, T. J., et al. (2014). Induction of p53-mediated transcription and
apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer
Sci. 105, 795–801. doi: 10.1111/cas.12430
Zanella, F., Lorens, J. B., and Link, W. (2010). High content screening: seeing is
believing. Trends Biotechnol. 28, 237–245. doi: 10.1016/j.tibtech.2010.02.005
Zheng, Y., Gery, S., Sun, H., Shacham, S., Kauffman, M., and Koeffler, H. P. (2014).
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative
activity in hepatocellular carcinoma. Cancer Chemother. Pharmacol. 74, 487–
495. doi: 10.1007/s00280-014-2495-8
Zhou, F., Qiu, W., Yao, R., Xiang, J., Sun, X., Liu, S., et al. (2013). CRM1 is a novel
independent prognostic factor for the poor prognosis of gastric carcinomas.
Med. Oncol. 30 (726). doi: 10.1007/s12032-013-0726-1
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Ferreira, Cautain, Grenho and Link. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.May 2020 | Volume 11 | Article 625
